NCT00166725View on ClinicalTrials.gov

Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 29, 2004

Conditions
Prostate Cancer
Interventions
DRUG

Octreotide LAR

Trial Locations (1)

Unknown

Orbassano, Orbassano

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY